Jove
Visualize
Contact Us

Related Experiment Videos

Pentasaccharides.

Alexander G G Turpie1

  • 1Hamilton Health Sciences-Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2 Canada.

Seminars in Hematology
|July 19, 2002
PubMed
Summary
This summary is machine-generated.

Fondaparinux sodium, a novel antithrombotic, selectively inhibits factor Xa. Clinical trials show its efficacy and safety in preventing and treating thromboembolic disorders, including venous thromboembolism and acute coronary syndromes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2024
Same author

Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of stroke.

Open heart·2023
Same author

Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry.

Thrombosis research·2023
Same author

Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry.

The American journal of medicine·2023
Same author

Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.

Thrombosis research·2023
Same author

Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.

Diabetes, obesity & metabolism·2023
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Hematology
  • Vascular Medicine

Background:

  • Current antithrombotic therapies have limitations.
  • Need for agents targeting factor Xa.
  • Development of selective factor Xa inhibitors.

Purpose of the Study:

  • Introduce fondaparinux sodium, a new class of antithrombotic.
  • Evaluate its potential in preventing and treating thromboembolic diseases.
  • Assess its pharmacokinetic profile, efficacy, and safety.

Main Methods:

  • Preclinical studies.
  • Clinical trials.
  • Pharmacokinetic profiling.

Main Results:

  • Fondaparinux sodium demonstrates a favorable pharmacokinetic profile.

Related Experiment Videos

  • Promising efficacy in preventing venous thromboembolism post-orthopedic surgery.
  • Effective in treating deep venous thrombosis and acute coronary syndromes.

    • Conclusions:

    • Fondaparinux sodium offers a new therapeutic option for thromboembolic disease.
    • The agent shows a good balance of efficacy and safety.
    • Further research supports its role in managing thrombotic conditions.